# A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

> **NCT03033498** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 29 (actual)

## Conditions studied

- Parkinson's Disease (PD)

## Interventions

- **DRUG:** ABBV-951

## Key facts

- **NCT ID:** NCT03033498
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-17
- **Primary completion:** 2019-06-08
- **Final completion:** 2019-06-08
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03033498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03033498, "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03033498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*